zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2014-11-2-3zdor-1483Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESЛЕФЛУНОМИД: ФАРМАКОЛОГИЧЕСКИЕ ОСОБЕННОСТИ (обзор литературы)LEFLUNOMIDE: PHARMACOLOGICAL CHARACTERISTICS (literature review)ВоловиковаО. Н.VolovikovaO. N.noemail@neicon.ruМихайловаЕ. И.MikhailovaE. I.noemail@neicon.ruДундароваГ. Г.DundarovaG. G.noemail@neicon.ruКарпенкоЕ. Э.KarpenkoE. E.noemail@neicon.ruГомельский государственный медицинский университетGomel State Medical UniversityГомельская областная клиническая больницаGomel Regional Clinical HospitalГомельская городская клиническая больница № 1Gomel Municipal Clinical Hospital № 1201428062014021821Copyright © Воловикова О.Н., Михайлова Е.И., Дундарова Г.Г., Карпенко Е.Э., 20142014Воловикова О.Н., Михайлова Е.И., Дундарова Г.Г., Карпенко Е.Э.Volovikova O.N., Mikhailova E.I., Dundarova G.G., Karpenko E.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/1483

В настоящее время в лечении ревматоидного артрита хорошей альтернативой метотрексату является новый лекарственный препарат «Лефлуномид». Он обладает способностью ингибировать ферменты - дигидрооротат дегидрогеназу и тирозинкиназу и приводить к развитию антипролиферативного, противовоспалительного, иммуносупрессивного и хондропротективного эффектов.

At present, Leflunomide is a good alternative to Methotrexate in the treatment for rheumatoid arthritis. It can inhibit two enzymes: dihydroorotate dehydrogenase and tyrosine kinase and lead to the development of antiproliferative, antiinflammatory, immunosuppressive and chondroprotective effects.

лефлуномидревматоидный артритфармакокинетикафармакодинамикаleflunomiderheumatoid arthritispharmacokineticspharmacodynamicsReferencesAlcorn, N. An appraisal of Leflunomide in 10 year after licensing / N. Alcorn, S. Saunders, R. Madhok // Drug Safety. - 2009. - № 32. - P. 1123-1134.Alcorn, N. An appraisal of Leflunomide in 10 year after licensing / N. Alcorn, S. Saunders, R. Madhok // Drug Safety. - 2009. - № 32. - P. 1123-1134.Насонов, Е. Л. Перспективы применения лефлуномида в ревматологии / Е. Л. Насонов, Н. В. Чичасова, К. А. Чижова. - M.: РМЖ, 2004. - № 12 (20). - P. 1147-1151.Насонов, Е. Л. Перспективы применения лефлуномида в ревматологии / Е. Л. Насонов, Н. В. Чичасова, К. А. Чижова. - M.: РМЖ, 2004. - № 12 (20). - P. 1147-1151.Fox, R. I. Mechanism of action of leflunomide in rheumatoid arthritis / R. J. Fox // J. Rheumatol Suppl. - 1998. - № 53. - P. 20-26.Fox, R. I. Mechanism of action of leflunomide in rheumatoid arthritis / R. J. Fox // J. Rheumatol Suppl. - 1998. - № 53. - P. 20-26.Hormones modulate the effects of leflunomide on cytokine production by cultures of differentiated monocyte/macrophages and synovial macrophages from rheumatoid arthritis patients / P. Montagna [et al.] // J. Autoimmun. - 2009. - № 32. - P. 254-260.Hormones modulate the effects of leflunomide on cytokine production by cultures of differentiated monocyte/macrophages and synovial macrophages from rheumatoid arthritis patients / P. Montagna [et al.] // J. Autoimmun. - 2009. - № 32. - P. 254-260.Чичасова, Н. В. Лефлуномид в терапии ревматоидного артрита. Симпозиум «Базисная противовоспалительная терапия ревматических заболеваний» / Н. В. Чичасова, В. Иголкина, Г. Р. Имаметдинова. - М., 2006. - 7 с.Чичасова, Н. В. Лефлуномид в терапии ревматоидного артрита. Симпозиум «Базисная противовоспалительная терапия ревматических заболеваний» / Н. В. Чичасова, В. Иголкина, Г. Р. Имаметдинова. - М., 2006. - 7 с.De´age, V. Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1beta and metalloproteinases / V. De´age, D. Burger, J. M. Dayer // Eur. Cytokine Netw. - 1998. - № 9. - P. 663-668.De´age, V. Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1beta and metalloproteinases / V. De´age, D. Burger, J. M. Dayer // Eur. Cytokine Netw. - 1998. - № 9. - P. 663-668.Six months open label trial of leflunomide in active ankylosing spondylitis / H. Haibel [et al.] // Ann. Rheum. Dis. - 2005. - № 64. - P. 124-126.Six months open label trial of leflunomide in active ankylosing spondylitis / H. Haibel [et al.] // Ann. Rheum. Dis. - 2005. - № 64. - P. 124-126.Gupta, R. Risk of hepatotoxicity with add on Leflunomide in a patient / R. Gupta, J. Bhatia, S. K. Gupta // Arzneimettelforschung. - 2011. - № 61. - P. 312-316.Gupta, R. Risk of hepatotoxicity with add on Leflunomide in a patient / R. Gupta, J. Bhatia, S. K. Gupta // Arzneimettelforschung. - 2011. - № 61. - P. 312-316.Yuyuan, L. Leflunomide-induced acute liver failure: a case report / L. Yuyuan, Z. Xuqing // J. Med. Coll. PLA. - 2010. - № 25. - P. 62-64.Yuyuan, L. Leflunomide-induced acute liver failure: a case report / L. Yuyuan, Z. Xuqing // J. Med. Coll. PLA. - 2010. - № 25. - P. 62-64.Internet website [Электронный ресурс]. - Режим доступа: http:// www.consilium-medicum.com/article/16554. - Дата доступа: 21.01.2014.Internet website [Электронный ресурс]. - Режим доступа: http:// www.consilium-medicum.com/article/16554. - Дата доступа: 21.01.2014.Internet website [Электронный ресурс]. - Дата доступа: 21.01.2014.Internet website [Электронный ресурс]. - Дата доступа: 21.01.2014.Rozman, B. Clinical Pharmacokinetics of Leflunomide / B. Rozman // Clin. Pharmacokinet. - 2002. - № 41. - P. 421-430.Rozman, B. Clinical Pharmacokinetics of Leflunomide / B. Rozman // Clin. Pharmacokinet. - 2002. - № 41. - P. 421-430.Blood Distribution and Single-Dose Pharmacokinetics of Leflunomide / J. Lucien [et al.] // Ther. Drug. Monit. - 1995. - № 17. - P. 454-459.Blood Distribution and Single-Dose Pharmacokinetics of Leflunomide / J. Lucien [et al.] // Ther. Drug. Monit. - 1995. - № 17. - P. 454-459.Bredveld, F. C. Leflunomide: Mode of action in the treatment of Rheumatoid Arthritis / F. C. Bredveld, J. Dayer // Ann. Rheum. Dis. - 2000. - № 59. - P. 841-849.Bredveld, F. C. Leflunomide: Mode of action in the treatment of Rheumatoid Arthritis / F. C. Bredveld, J. Dayer // Ann. Rheum. Dis. - 2000. - № 59. - P. 841-849.Herrmann, M. L. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases / M. L. Herrmann, R. Schleyerbach, B. J. Kirschbaum // Immunopharmacol. - 2000. - № 47. - P. 273-289.Herrmann, M. L. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases / M. L. Herrmann, R. Schleyerbach, B. J. Kirschbaum // Immunopharmacol. - 2000. - № 47. - P. 273-289.Matthias, L. H. Leflunomide in the Treatment of Rheumatoid Arthritis / L. H. Matthias, S. Rudolf, J. K. Bernhard // Clin. Ther. - 2004. - № 26. - P. 447-459.Matthias, L. H. Leflunomide in the Treatment of Rheumatoid Arthritis / L. H. Matthias, S. Rudolf, J. K. Bernhard // Clin. Ther. - 2004. - № 26. - P. 447-459.Rezzonico, R. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E2, matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes / R. Rezzonico, D. Burger, J. M. Dayer // Rheumatology. - 2003. - № 42. - P. 89-96.Rezzonico, R. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E2, matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes / R. Rezzonico, D. Burger, J. M. Dayer // Rheumatology. - 2003. - № 42. - P. 89-96.Brazleton, T. R. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide / T. R. Brazleton, R. E. Morris // Curr. Opin. Immunol. - 1996. - № 8. - P. 710-720.Brazleton, T. R. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide / T. R. Brazleton, R. E. Morris // Curr. Opin. Immunol. - 1996. - № 8. - P. 710-720.The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism / H. M. Cherwinski [et al.] // J. Pharmacol. Exp. Ther. - 1995. - № 272. - P. 460-468.The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism / H. M. Cherwinski [et al.] // J. Pharmacol. Exp. Ther. - 1995. - № 272. - P. 460-468.The immunosuppressive metabolite of leflunomide, A771726, affects murine T cells through two biochemical mechanisms / R. T. Elder [et al.] // J. Immunol. - 1997. - № 159. - P. 22-27.The immunosuppressive metabolite of leflunomide, A771726, affects murine T cells through two biochemical mechanisms / R. T. Elder [et al.] // J. Immunol. - 1997. - № 159. - P. 22-27.Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis / R. R. Bartlett [et al.] // Transplant Proc. - 1996. - № 28. - P. 3074-3078.Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis / R. R. Bartlett [et al.] // Transplant Proc. - 1996. - № 28. - P. 3074-3078.Leflunomide protects from T-cell mediated liver injury in mice through inhibition of nuclear factor kB / M. Imose [et al.] // Hepatology. - 2004. - № 40. - P. 1160-1170.Leflunomide protects from T-cell mediated liver injury in mice through inhibition of nuclear factor kB / M. Imose [et al.] // Hepatology. - 2004. - № 40. - P. 1160-1170.Suppressive effect of leflunomide on Leptin-induced collagen I production involved in hepatic stellate cell proliferation / H. F. Si [et al.] // Exp. Biol. Med. - 2007. - № 232. - P. 427-436.Suppressive effect of leflunomide on Leptin-induced collagen I production involved in hepatic stellate cell proliferation / H. F. Si [et al.] // Exp. Biol. Med. - 2007. - № 232. - P. 427-436.Hoskin, D. W. Dose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction / D. W. Hoskin, R. M. Taylor, A. P. Makrigiannis // Int. J. Immunopharmacol. - 1998. - № 20. - P. 505-513.Hoskin, D. W. Dose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction / D. W. Hoskin, R. M. Taylor, A. P. Makrigiannis // Int. J. Immunopharmacol. - 1998. - № 20. - P. 505-513.Waldman, W. J. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide / W. J. Waldman, D. A. Knight, N. S. Lurain // Transplant. - 1999. - № 68. - P. 814-825.Waldman, W. J. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide / W. J. Waldman, D. A. Knight, N. S. Lurain // Transplant. - 1999. - № 68. - P. 814-825.In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: Mechanisms of action / Xu. Xiulong [et al.] // Biochem. Pharmacol. - 1999. - № 58. - P. 1404-1413.In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: Mechanisms of action / Xu. Xiulong [et al.] // Biochem. Pharmacol. - 1999. - № 58. - P. 1404-1413.The active metabolite of Leflunomide, A771726 increases the production of IL-1 receptor antagonist in human synovial fibroblast and articular chondrocytes / G. Palmer [et al.] // Arth. Res. Therapy. - 2004. - № 6. - P. 181-189.The active metabolite of Leflunomide, A771726 increases the production of IL-1 receptor antagonist in human synovial fibroblast and articular chondrocytes / G. Palmer [et al.] // Arth. Res. Therapy. - 2004. - № 6. - P. 181-189.Active leflunomide metabolite inhibits interleukin 1b, tumour necrosis factor a, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures / O. Elkayam [et al.] // Ann. Rheum. Dis. - 2003. - № 62. - P. 440-443.Active leflunomide metabolite inhibits interleukin 1b, tumour necrosis factor a, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures / O. Elkayam [et al.] // Ann. Rheum. Dis. - 2003. - № 62. - P. 440-443.Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells / P. Baumann [et al.] // Mol. Cancer Ther. - 2009. - № 8. - P. 366-375.Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells / P. Baumann [et al.] // Mol. Cancer Ther. - 2009. - № 8. - P. 366-375.Regulation of B cell function by the immunosuppressive agent leflunomide / K. F. Siemasko [et al.] // Transplantation. - 1996. - № 61. - P. 635-642.Regulation of B cell function by the immunosuppressive agent leflunomide / K. F. Siemasko [et al.] // Transplantation. - 1996. - № 61. - P. 635-642.

The authors declare that there are no conflicts of interest present.